HER2 gene amplification

3 trials 2 recruiting MedDRA PT
3 Registered trials
2 Recruiting
3 Unique sponsors
3 Unique IMPs
1 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Monoclonal antibody (tumor, humanized) 2 substances
Antibody-drug conjugate (ADC) 1 substance
Phase II: 1 Phase I: 2

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase II

1 trial
  • BOOG Study Center B.V. Academic
    PERTUZUMAB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE
    2024-516205-23-00 1 country 2019 n=472
    Ended

Phase I

2 trials
  • Iambic Therapeutics Inc. Commercial
    IMP not specified
    2024-519188-17-00 5 countries 2025 n=97
    Recruiting
  • Rigshospitalet Academic
    IMP not specified
    2024-516786-37-00 1 country 2025 n=140
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Iambic Therapeutics Inc. Commercial 1 Phase I 1
Rigshospitalet Academic 1 Phase I 1
BOOG Study Center B.V. Academic 1 Phase II 0
New trials by year
2019
1
2025
2
← All indication landscapes